Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
JAMA Oncology – April 13, 2023
Source: OpenAlex
Summary
A nonrandomized controlled trial explored psilocybin, a powerful hallucinogen, as a potential rapidly effective medicine for major depressive disorder in patients with cancer. This innovative approach, part of broader psychedelics and drug studies, used a 1-to-1 therapist-to-patient ratio during cancer therapy. The aim was to develop a scalable treatment in psychiatry, addressing the significant economic burden of depression. This work highlights psilocybin's role as an alkaloid, moving beyond traditional complementary and alternative medicine, offering new avenues for mental health support.
Abstract
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.